Active — Not RecruitingNot Applicable

An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma

United States19 participantsStarted 2021-04-06

Plain-language summary

The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also called contrast-enhanced CT scans). All participants in this study will have pancreatic ductal adenocarcinoma (PDAC) that has spread (metastasized) to the liver, and all participants will be scheduled for a routine CT scan that will measure their cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and female patients, 18 years of age or older * Confirmed diagnosis of PDAC or GI tract adenocarcinoma metastatic to liver * Scheduled for imaging with contrast enhanced CT Exclusion Criteria: * Inability to tolerate intravenous contrast medium * All liver metastases ≤ 10 mm in maximal diameter on the contrast enhanced CT used for comparison to the planned research ultrasound * Multiple confluent liver metastases or tumor burden \> 50% of the liver as estimated by a radiologist

What they're measuring

measurement differences between ultrasound tumor volumes

Timeframe: 1 year

Trial details

NCT IDNCT04837833

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-04-06

View on ClinicalTrials.gov More Pancreas Cancer trials